- Home
- API vs PRTA Comparison
API vs PRTA Comparison
Compare API & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- PRTA
- Stock Information
- Founded
- API 2013
- PRTA 2012
- Country
- API United States
- PRTA Ireland
- Employees
- API N/A
- PRTA N/A
- Industry
- API Computer Software: Prepackaged Software
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- API Technology
- PRTA Health Care
- Exchange
- API Nasdaq
- PRTA Nasdaq
- Market Cap
- API 343.2M
- PRTA 472.1M
- IPO Year
- API 2020
- PRTA N/A
- Fundamental
- Price
- API $3.45
- PRTA $8.20
- Analyst Decision
- API Strong Buy
- PRTA Buy
- Analyst Count
- API 1
- PRTA 10
- Target Price
- API $6.00
- PRTA $14.86
- AVG Volume (30 Days)
- API 482.6K
- PRTA 1.2M
- Earning Date
- API 08-18-2025
- PRTA 08-04-2025
- Dividend Yield
- API N/A
- PRTA N/A
- EPS Growth
- API N/A
- PRTA N/A
- EPS
- API N/A
- PRTA N/A
- Revenue
- API $133,554,000.00
- PRTA $10,341,000.00
- Revenue This Year
- API $7.20
- PRTA N/A
- Revenue Next Year
- API $11.26
- PRTA $389.77
- P/E Ratio
- API N/A
- PRTA N/A
- Revenue Growth
- API N/A
- PRTA N/A
- 52 Week Low
- API $1.78
- PRTA $4.32
- 52 Week High
- API $6.99
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- API 40.21
- PRTA 58.73
- Support Level
- API $3.48
- PRTA $8.05
- Resistance Level
- API $3.67
- PRTA $8.73
- Average True Range (ATR)
- API 0.19
- PRTA 0.38
- MACD
- API -0.02
- PRTA -0.05
- Stochastic Oscillator
- API 10.17
- PRTA 47.62
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.